|
Medical device maker Covidien PLC’s pharmaceutical arm, Mallinckrodt, has completed its acquisition of St. Paul, Minn.-based CNS Therapeutics Inc. for roughly $100 million.
more
By PBN Staff
|
|
The Norman Prince Neurosciences Institute at Rhode Island Hospital was awarded three philanthropic gifts totaling nearly $600,000 to improve brain science in the state of Rhode Island by supporting research and establishing a lecture series.
more
By Emily Greenhalgh |
|
During the fiscal year ended June 30, the National Institutes of Health awarded a total of $146.96 million in grants to Rhode Island hospitals, universities and companies.
more
By Emily Greenhalgh |
|
The R.I. Economic Development Corporation approved a corporate tax cut Monday night for Alexion Pharmaceuticals under the state’s Jobs Development Act.
more
By Patrick Anderson |
|
QuickLabel Systems, a brand of Astro-Med Inc., held the ribbon cutting ceremony to inaugurate its revamped QuickLabel College Lab.
more
By Emily Greenhalgh |
|
Thousand Oaks, Calif.–based Amgen, one of the world’s largest biotechnology companies, saw revenue rise 9.5 percent to $4.3 billion in the three months ended Sept. 30 from $3.9 billion during the same period in 2011.
more
By PBN Staff
|
|
PROVIDENCE – The implementation of the primary-care provider-designation law taking effect on Jan. 1 is moving forward. Under the new law, health insurers will need to submit plans to the R.I. Office of the Health Insurance Commissioner (OHIC) to ensure that they will meet the law’s requirements.
more
11/19/12
|
|
PROVIDENCE – A new study by The Miriam Hospital researcher Robyn L. Fielder published online by the Journal of Adolescent Health has found that romantic encounters are the most common sexual behavior among women in their first year of college.
more
11/19/12
|
|
There has been a lot of talk about the fact that we are now entering the Knowledge Age in American business. Terms such as Knowledge Economy, Knowledge Worker and even Knowledge Districts are becoming more common every day. But to date most of those using the terms have been intellectuals, academics and those who deal in emergent industries.
more
11/19/12
|
|
At
By John Larrabee
Contributing Writer | 12/3/12 |
